128 related articles for article (PubMed ID: 19487811)
1. Molecular disruption of RAD50 sensitizes human tumor cells to cisplatin-based chemotherapy.
Abuzeid WM; Jiang X; Shi G; Wang H; Paulson D; Araki K; Jungreis D; Carney J; O'Malley BW; Li D
J Clin Invest; 2009 Jul; 119(7):1974-85. PubMed ID: 19487811
[TBL] [Abstract][Full Text] [Related]
2. Heterozygous RAD50 gene variant in a family with systemic sclerosis suggests role of impaired DNA repair mechanisms in disease pathogenesis.
Machhua S; Sharma SK; Minz RW; Pandey SK; Jindal A; Rawat A; Jindal AK
Clin Exp Dermatol; 2024 Apr; 49(5):543-546. PubMed ID: 38060685
[No Abstract] [Full Text] [Related]
3. Targeting Rad50 sensitizes human nasopharyngeal carcinoma cells to radiotherapy.
Chang L; Huang J; Wang K; Li J; Yan R; Zhu L; Ye J; Wu X; Zhuang S; Li D; Zhang G
BMC Cancer; 2016 Mar; 16():190. PubMed ID: 26951044
[TBL] [Abstract][Full Text] [Related]
4. Response to MEK inhibitor in small cell neuroendocrine carcinoma of the cervix with a KRAS mutation.
Lyons YA; Frumovitz M; Soliman PT
Gynecol Oncol Rep; 2014 Dec; 10():28-9. PubMed ID: 26075998
[TBL] [Abstract][Full Text] [Related]
5. RAD50 targeting impairs DNA damage response and sensitizes human breast cancer cells to cisplatin therapy.
Flores-Pérez A; Rafaelli LE; Ramírez-Torres N; Aréchaga-Ocampo E; Frías S; Sánchez S; Marchat LA; Hidalgo-Miranda A; Quintanar-Jurado V; Rodríguez-Cuevas S; Bautista-Piña V; Carlos-Reyes A; López-Camarillo C
Cancer Biol Ther; 2014 Jun; 15(6):777-88. PubMed ID: 24642965
[TBL] [Abstract][Full Text] [Related]
6. Dual disruption of DNA repair and telomere maintenance for the treatment of head and neck cancer.
Lajud SA; Nagda DA; Yamashita T; Zheng J; Tanaka N; Abuzeid WM; Civantos A; Bezpalko O; O'Malley BW; Li D
Clin Cancer Res; 2014 Dec; 20(24):6465-78. PubMed ID: 25324139
[TBL] [Abstract][Full Text] [Related]
7. The Nrf2 transcription factor contributes to resistance to cisplatin in bladder cancer.
Hayden A; Douglas J; Sommerlad M; Andrews L; Gould K; Hussain S; Thomas GJ; Packham G; Crabb SJ
Urol Oncol; 2014 Aug; 32(6):806-14. PubMed ID: 24837013
[TBL] [Abstract][Full Text] [Related]
8. Rad50 zinc hook is important for the Mre11 complex to bind chromosomal DNA double-stranded breaks and initiate various DNA damage responses.
He J; Shi LZ; Truong LN; Lu CS; Razavian N; Li Y; Negrete A; Shiloach J; Berns MW; Wu X
J Biol Chem; 2012 Sep; 287(38):31747-56. PubMed ID: 22833675
[TBL] [Abstract][Full Text] [Related]
9. MRE11 expression is predictive of cause-specific survival following radical radiotherapy for muscle-invasive bladder cancer.
Choudhury A; Nelson LD; Teo MT; Chilka S; Bhattarai S; Johnston CF; Elliott F; Lowery J; Taylor CF; Churchman M; Bentley J; Knowles MA; Harnden P; Bristow RG; Bishop DT; Kiltie AE
Cancer Res; 2010 Sep; 70(18):7017-26. PubMed ID: 20843819
[TBL] [Abstract][Full Text] [Related]
10. Head and neck squamous cell carcinoma targeted chemosensitization.
Figures MR; Wobb J; Araki K; Liu T; Xu L; Zhu H; O'Malley BW; Li D
Otolaryngol Head Neck Surg; 2009 Aug; 141(2):177-83. PubMed ID: 19643248
[TBL] [Abstract][Full Text] [Related]
11. Ipatasertib, an oral AKT inhibitor, in combination with carboplatin exhibits anti-proliferative effects in uterine serous carcinoma.
Burkett WC; Zhao Z; Newton MA; Sun W; Deng B; Secord AA; Zhou C; Bae-Jump V
Ann Med; 2023 Dec; 55(1):603-614. PubMed ID: 36773034
[TBL] [Abstract][Full Text] [Related]
12. Cisplatin-induced cell death increases the degradation of the MRE11-RAD50-NBS1 complex through the autophagy/lysosomal pathway.
Belmonte-Fernández A; Herrero-Ruíz J; Galindo-Moreno M; Limón-Mortés MC; Mora-Santos M; Sáez C; Japón MÁ; Tortolero M; Romero F
Cell Death Differ; 2023 Feb; 30(2):488-499. PubMed ID: 36477079
[TBL] [Abstract][Full Text] [Related]
13. DNA Repair Mechanisms, Protein Interactions and Therapeutic Targeting of the MRN Complex.
McCarthy-Leo C; Darwiche F; Tainsky MA
Cancers (Basel); 2022 Oct; 14(21):. PubMed ID: 36358700
[TBL] [Abstract][Full Text] [Related]
14. HDAC Inhibitor Sodium Butyrate Attenuates the DNA Repair in Transformed but Not in Normal Fibroblasts.
Gnedina OO; Morshneva AV; Skvortsova EV; Igotti MV
Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35408878
[TBL] [Abstract][Full Text] [Related]
15. Multiomic analysis identifies CPT1A as a potential therapeutic target in platinum-refractory, high-grade serous ovarian cancer.
Huang D; Chowdhury S; Wang H; Savage SR; Ivey RG; Kennedy JJ; Whiteaker JR; Lin C; Hou X; Oberg AL; Larson MC; Eskandari N; Delisi DA; Gentile S; Huntoon CJ; Voytovich UJ; Shire ZJ; Yu Q; Gygi SP; Hoofnagle AN; Herbert ZT; Lorentzen TD; Calinawan A; Karnitz LM; Weroha SJ; Kaufmann SH; Zhang B; Wang P; Birrer MJ; Paulovich AG
Cell Rep Med; 2021 Dec; 2(12):100471. PubMed ID: 35028612
[TBL] [Abstract][Full Text] [Related]
16. RAD50 deficiency is a predictor of platinum sensitivity in sporadic epithelial ovarian cancers.
Alblihy A; Alabdullah ML; Toss MS; Algethami M; Mongan NP; Rakha EA; Madhusudan S
Mol Biomed; 2020 Dec; 1(1):19. PubMed ID: 35006434
[TBL] [Abstract][Full Text] [Related]
17.
Ko JMY; Lam SY; Ning L; Chai AWY; Lei LC; Choi SSA; Wong CWY; Lung ML
Cancers (Basel); 2021 Sep; 13(18):. PubMed ID: 34572942
[TBL] [Abstract][Full Text] [Related]
18. Targeting DNA Damage Response and Repair to Enhance Therapeutic Index in Cisplatin-Based Cancer Treatment.
Kiss RC; Xia F; Acklin S
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360968
[TBL] [Abstract][Full Text] [Related]
19. Microbiome dysbiosis in lung cancer: from composition to therapy.
Liu NN; Ma Q; Ge Y; Yi CX; Wei LQ; Tan JC; Chu Q; Li JQ; Zhang P; Wang H
NPJ Precis Oncol; 2020 Dec; 4(1):33. PubMed ID: 33303906
[TBL] [Abstract][Full Text] [Related]
20. The forkhead box M1 (FOXM1) expression and antitumor effect of FOXM1 inhibition in malignant rhabdoid tumor.
Shibui Y; Kohashi K; Tamaki A; Kinoshita I; Yamada Y; Yamamoto H; Taguchi T; Oda Y
J Cancer Res Clin Oncol; 2021 May; 147(5):1499-1518. PubMed ID: 33221995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
